Skip to content

Asenapine

SGA • Last reviewed 2025-09-26

Brands: Saphris, Secuado

Sources updated 2025 • 1 references

Summary

General Information

Indicated for: Schizophrenia; acute treatment of manic or mixed episodes associated with bipolar I disorder (monotherapy or adjunct). Second‑generation antipsychotic (SGA)

Dosage & Administration

Typical dose range: 5–10 mg SL BID

Indications (label)

Schizophrenia; acute treatment of manic or mixed episodes associated with bipolar I disorder (monotherapy or adjunct).

View labelExact

Mechanism (brief)

Antagonist at D2/D3 and 5‑HT2A receptors with additional α1 and H1 blockade.

Metabolism & Half‑life

  • Metabolism: UGT1A4 glucuronidation and CYP1A2 oxidation.
  • Half‑life: ~24 h (sublingual); ~30 h (transdermal).

Therapeutic Drug Monitoring (TDM)

Recommended: No

References